CARBON DIOXIDE, USP (carbon dioxide) by Martin Pharmaceuticals is x-ray contrast activity [moa]. First approved in 2025.
Drug data last refreshed 13h ago · AI intelligence enriched 2d ago
Carbon Dioxide, USP is an inhaled gas product approved as a radiographic contrast agent for X-ray imaging procedures. It functions through X-ray contrast activity to enhance visualization during diagnostic imaging. This product represents a novel application of a common gas in medical diagnostics.
Early-stage launch product with emerging commercial potential; team building and market establishment phase underway.
X-Ray Contrast Activity
Radiographic Contrast Agent
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Study of the Efficacy and Safety of Extracorporeal Carbon Dioxide Removal Using PrismaLung+
Extracorporeal Carbon Dioxide Removal Using PrismaLung in Reducing Ventilator Induced Lung Injury
Carbon Dioxide Investigation
Influence of Caffeine on Psychomotor Vigilance and Carbon Dioxide Tolerance During Graded Hypercapnia
RECELL to Promote Healing Following Carbon Dioxide (CO2) Laser Treatment in Cosmetic Patients
Worked on CARBON DIOXIDE, USP at Martin Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
This is an early-stage launch opportunity with minimal current job openings but significant potential for team growth as market adoption increases. Professionals joining now will have visibility into market creation and differentiation strategy in an emerging diagnostic modality.